Keith S. Manchester - 14 Aug 2024 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Role
Director
Signature
/s/ David C. Hastings as attorney-in-fact for Keith S. Manchester
Issuer symbol
ABUS
Transactions as of
14 Aug 2024
Net transactions value
-$1,885
Form type
4
Filing time
16 Aug 2024, 16:07:41 UTC
Previous filing
24 May 2024
Next filing
12 Sep 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABUS Common Shares Options Exercise $30,752 +54,915 $0.5600* 54,915 14 Aug 2024 Direct F1
transaction ABUS Common Shares Sale $32,637 -8,846 -16% $3.69 46,069 14 Aug 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABUS Stock Option (Right to Buy) Options Exercise $0 -54,915 -100% $0.000000* 0 14 Aug 2024 Common Shares 54,915 $0.5600 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Cashless exercise and hold transaction in director stock options due to expire on November 13, 2024, ten years after such options were granted, including the sale of 8,846 of the underlying shares to pay the exercise price. None of the net 46,069 shares were sold.
F2 This is a director stock option grant that is fully vested.